View Older Stories View More Recent Stories

May 8, 2018 07:30AM Zynerba Pharmaceuticals Reports First Quarter 2018 Financial Results and Operational Highlights
May 8, 2018 07:30AM Zynerba Pharmaceuticals Reports First Quarter 2018 Financial Results and Operational Highlights
Apr 25, 2018 07:13AM Zynerba Pharma (ZYNE) Announces Twelve Month ZYN002 Data from STAR 2 Study in Patients with Focal Seizures at AAN
Apr 25, 2018 07:00AM Zynerba Pharmaceuticals Announces Twelve Month ZYN002 Data from STAR 2 Study in Patients with Focal Seizures at the 2018 Annual Meeting of the American Academy of Neurology (AAN)
Apr 23, 2018 07:00AM Zynerba Pharmaceuticals Announces Oral Presentation of ZYN002 Data at the 16th NFXF International Fragile X Conference in July 2018
Apr 16, 2018 07:02AM Zynerba Pharma (ZYNE) Names John P. Butler to Board
Apr 16, 2018 07:00AM Zynerba Pharmaceuticals Appoints John P. Butler to Board of Directors
Apr 10, 2018 07:03AM Zynerba Pharma (ZYNE) Initiates Open-Label Phase 2 Trial of ZYN002 in Developmental and Epileptic Encephalopathies
Apr 10, 2018 07:00AM Zynerba Pharmaceuticals Initiates Open-Label Phase 2 Trial of ZYN002 in Developmental and Epileptic Encephalopathies (DEE)
Mar 26, 2018 07:03AM Zynerba Pharma (ZYNE) Announces Publication of Preclinical Data in Neuropsychopharmacology
Mar 26, 2018 07:00AM Zynerba Pharmaceuticals Announces Publication of Preclinical Data in Neuropsychopharmacology Demonstrating Effect of Cannabidiol Gel Treatment in Reduction of Relapse in an Addiction Model
Mar 22, 2018 06:45AM Zynerba Pharmaceuticals Announces Poster Presentation at the 2018 Annual Meeting of the American Academy of Neurology (AAN)
Mar 14, 2018 09:00AM Zynerba Pharmaceuticals to Present at the Oppenheimer 28th Annual Healthcare Conference
Mar 12, 2018 06:45AM Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Operational Highlights
Mar 12, 2018 06:45AM Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Operational Highlights
Mar 5, 2018 06:46AM Zynerba (ZYNE) Announces Positive Meeting with FDA and Plans to Conduct Single Pivotal Study of ZYN002 in Fragile X Syndrome to Support an NDA Filing
Mar 5, 2018 06:45AM Zynerba Pharmaceuticals Announces Positive Meeting with U.S. Food and Drug Administration and Plans to Conduct a Single Pivotal Study of ZYN002 in Fragile X Syndrome to Support an NDA Filing
Mar 5, 2018 06:45AM Zynerba Pharmaceuticals Announces Positive Meeting with U.S. Food and Drug Administration and Plans to Conduct a Single Pivotal Study of ZYN002 in Fragile X Syndrome to Support an NDA Filing
Jan 3, 2018 04:32PM Zynerba Pharma (ZYNE) Announces Clinical and Corporate Update for 2018
Jan 3, 2018 04:30PM Zynerba Pharmaceuticals Provides 2018 Clinical and Corporate Update
Jan 3, 2018 04:30PM Zynerba Pharmaceuticals Provides 2018 Clinical and Corporate Update
Dec 4, 2017 09:09AM Zynerba Pharma (ZYNE) Positive ZYN002 Data from STAR 1 and STAR 2 Presented at AES
Dec 3, 2017 12:01PM Zynerba Pharmaceuticals Announces New ZYN002 Data from STAR 1 and STAR 2 Studies in Patients with Focal Seizures at the 2017 Annual Meeting of the American Epilepsy Society (AES)
Nov 21, 2017 09:03AM Zynerba Pharma (ZYNE) Announces Poster Presentation at AES
Nov 21, 2017 09:00AM Zynerba Pharmaceuticals Announces Poster Presentation at the 2017 Annual Meeting of the American Epilepsy Society (AES)
Nov 14, 2017 07:30AM Zynerba Pharmaceuticals Reports Third Quarter 2017 Financial Results and Operational Highlights
Nov 7, 2017 07:30AM Zynerba Pharmaceuticals to Present at Upcoming Investor Conferences
Sep 28, 2017 06:31AM Zynerba Pharma (ZYNE) ZYN002 Open Label Phase 2 FAB-C Study in Children with Fragile X Syndrome Met Primary Endpoint
Sep 28, 2017 06:30AM Zynerba Pharmaceuticals Announces Positive Top Line Results in ZYN002 Open Label Phase 2 FAB-C Study in Children with Fragile X Syndrome
Sep 6, 2017 07:30AM Zynerba Pharmaceuticals to Participate in Upcoming Investor Conferences
Aug 14, 2017 06:47AM Zynerba Pharma (ZYNE) Says Phase 2 STOP Trial of ZYN002 in Osteoarthritis Didn't Meet Primary Endpoint
Aug 14, 2017 06:45AM Zynerba Pharmaceuticals Announces that Results from Phase 2 STOP Trial Support Continued Development of ZYN002 in Osteoarthritis
Aug 7, 2017 06:47AM Zynerba Pharma (ZYNE) Phase 2 STAR 1 Did Not Demonstrate Statistical Significance
Aug 7, 2017 06:45AM Zynerba Pharmaceuticals Announces Top-Line Results from Phase 2 STAR 1 Trial of ZYN002 in Adult Epilepsy Patients with Focal Seizures
Aug 1, 2017 07:30AM Zynerba Pharmaceuticals Reports Second Quarter 2017 Financial Results and Operational Highlights
Jun 26, 2017 07:45AM Zynerba Pharmaceuticals Added to the Russell 3000® Index
Jun 26, 2017 07:33AM Zynerba Pharma (ZYNE) Initiates ZYN001 Phase 1 Study
Jun 26, 2017 07:30AM Zynerba Pharmaceuticals Initiates ZYN001 Phase 1 Clinical Program
Jun 8, 2017 07:35AM Zynerba Pharma (ZYNE) Completes Target Enrollment in Exploratory Phase 2 Trial of ZYN002 in Fragile X Syndrome
Jun 8, 2017 07:30AM Zynerba Pharmaceuticals Achieves Target Enrollment in Exploratory Phase 2 Trial of ZYN002 in Fragile X Syndrome
Jun 1, 2017 08:16AM Zynerba Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare Conference
May 9, 2017 07:30AM Zynerba Pharmaceuticals Reports First Quarter 2017 Financial Results and Operational Highlights
Mar 27, 2017 06:30AM Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results and Operational Highlights
Mar 13, 2017 07:35AM Zynerba Pharmaceuticals to Report Fourth Quarter and Full-Year 2016 Financial and Operating Results on March 27, 2017
Mar 13, 2017 07:33AM Zynerba Pharma (ZYNE) Completes Enrollment for ZYN002 in Two Phase 2 Trials for
Mar 13, 2017 07:30AM Zynerba Pharmaceuticals Announces Completion of Enrollment for ZYN002 in Two Phase 2 Clinical Trials for Epilepsy and Osteoarthritis
Mar 1, 2017 07:00AM Zynerba Pharmaceuticals to Participate in Upcoming Investor Conferences
Feb 9, 2017 07:35AM Zynerba Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
Jan 19, 2017 09:17AM Zynerba Pharma (ZYNE) Prices 2.8M Shares at $18 Per Share
Jan 19, 2017 09:16AM Zynerba Pharmaceuticals Announces Pricing of Public Offering of Common Stock
View More Recent Stories View Older Stories